Market Signal Briefing

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

AUSTIN, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and data feed optimization leader Feedonomics, today announced its endorsement of Google’s new Universal Commerce Protocol (UCP).

The new, open-source standard creates a common language for agents and systems to work together across the entire shopping journey from discovery and buying to post-purchase experiences. So instead of building a new connection for every agent, they can all interact seamlessly providing merchants with a frictionless way to reach customers across the entire AI ecosystem.

“AI is rapidly reshaping commerce. Merchants need to make it easy for shoppers to go from discovery to purchase, or they risk losing sales,” said Sharon Gee, senior vice president of product for AI at Commerce. “At the same time, keeping product data structured and enriched for AI can be resource-intensive. Our ongoing work with Google ensures merchants are not only present but competitive in AI-driven environments where consumers are searching and shopping.”

To start, UCP will soon enable a new checkout feature on product listings in AI Mode in Search and the Gemini app, allowing shoppers to buy directly from eligible US retailers and Commerce merchants right as they’re researching on Google.

“For agentic commerce to scale, it’s critical for the industry to align on a common set of standards,” said Ashish Gupta, vice president and general manager of merchant shopping at Google. “We are proud to have Commerce endorse the Universal Commerce Protocol as the foundation for that future.”

Discovery is shifting from traditional search that returns results to a specific query to conversational answer engines with embedded buying opportunities. Agent-driven shopping generates more specific, higher intent queries with consumers who know what they want and are ready to purchase it. Merchants must be strategic about how they show up in answer engines and remove barriers that prevent shoppers from making a purchase.

As part of the collaboration, Commerce is building toward the protocol to allow merchants to:

Enable buying directly within Google’s AI experiences, helping to secure transactions at the moment of intentRemain merchant of record, retaining full ownership of the customer relationship and transaction dataFuture-proof their business with a unified open standard to power additional commerce actions
The UCP endorsement builds on the ongoing Google and Commerce partnership, utilizing Commerce’s key differentiator: its Feedonomics-powered data enrichment layer. This layer structures and optimizes product feeds to align with Google’s schema, dynamically enhancing titles, attributes, and taxonomy to ensure high-quality data that boosts product visibility, improves match rates, and conversion with the Google ecosystem.

Learn more about Google’s new UCP here: https://blog.google/products/ads-commerce/agentic-commerce-ai-tools-protocol-retailers-platforms/

Learn more about how Commerce is powering the era of agentic commerce here: https://www.commerce.com/agentic-commerce/

About Commerce
Commerce (Nasdaq: CMRC) empowers businesses to innovate, grow, and thrive by providing an open, AI-driven commerce ecosystem. As the parent company of BigCommerce, Feedonomics, and Makeswift, Commerce connects the tools and systems that power growth, enabling businesses to unlock the full potential of their data, deliver seamless and personalized experiences across every channel, and adapt swiftly to an ever-changing market. Trusted by leading businesses like Coldwater Creek, Cole Haan, Harvey Nichols, King Arthur Baking Co., Mizuno, Perry Ellis, SportsShoes and Uplift Desk, Commerce delivers the storefront control, optimized data, and AI-ready tools businesses need to grow, serve diverse buyers, and operate with confidence in an increasingly intelligent, multi-surface world. For more information, visit commerce.com or follow us on X and LinkedIn.

BigCommerce®, the Commerce logo, and other brands are the trademarks or registered trademarks of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owner.

Media Contact:
Brad Hem
[email protected]

Darius Baruo Jan 11, 2026 13:31

WLD Price Prediction Summary • Short-term target (1 week): $0.60-$0.62 • Medium-term forecast (1 month): $0.54-$0.68 range • Bullish breakout level: $0.65 • Critical support: $0.56 What Crypt...

WLD Price Prediction Summary • Short-term target (1 week): $0.60-$0.62 • Medium-term forecast (1 month): $0.54-$0.68 range
• Bullish breakout level: $0.65 • Critical support: $0.56

What Crypto Analysts Are Saying About Worldcoin While specific analyst predictions from major cryptocurrency influencers are limited in recent trading sessions, available forecast data presents a mixed outlook for Worldcoin's price trajectory. According to CoinCodex's January 9th analysis, WLD was predicted to experience downward pressure toward $0.390299, though this forecast appears increasingly disconnected from current market reality given the token's stability above $0.57.

MEXC's more recent prediction suggested a target of $0.5744 for today's trading session, which aligns closely with the current price action around $0.58. On-chain metrics and technical indicators suggest the token is consolidating within a defined range as traders await direction signals.

WLD Technical Analysis Breakdown Worldcoin's current technical picture reveals a cryptocurrency in transition between bearish and bullish momentum. The RSI reading of 53.31 places WLD firmly in neutral territory, indicating neither oversold nor overbought conditions. This neutral RSI suggests room for movement in either direction based on market catalysts.

The MACD analysis presents mixed signals with the MACD line at 0.0089 matching the signal line, resulting in a histogram reading of 0.0000. This convergence indicates bearish momentum may be weakening, potentially setting up for a directional breakout.

Bollinger Bands analysis shows WLD trading at 67% of the band width, positioned between the middle band at $0.54 and upper band at $0.65. This positioning suggests the token has room to test the upper resistance before reaching technically overbought levels.

Moving average analysis reveals short-term bullishness with price trading above the EMA 12 ($0.57) and EMA 26 ($0.56). However, the SMA 200 at $0.92 indicates WLD remains significantly below its longer-term trend, suggesting the broader downtrend remains intact.

Worldcoin Price Targets: Bull vs Bear Case Bullish Scenario The bullish case for WLD price prediction centers on a break above the immediate resistance at $0.60, which coincides with the 7-day simple moving average. Successful momentum above this level could propel Worldcoin toward the Bollinger Band upper limit at $0.65, representing a 12% upside potential from current levels.

Technical confirmation for this bullish scenario would require sustained trading above $0.60 with increasing volume, RSI climbing toward 60-65 range, and positive MACD histogram development. The Stochastic indicators showing %K at 57.23 above %D at 45.79 support near-term bullish momentum.

Bearish Scenario The bearish Worldcoin forecast scenario involves a breakdown below the strong support level at $0.56, which aligns closely with both EMAs. Failure to hold this support could trigger selling pressure toward the Bollinger Band lower boundary at $0.44, representing a 24% downside risk.

Risk factors supporting the bearish case include the significant gap between current price and the SMA 200 at $0.92, indicating underlying weakness in the longer-term trend. Additionally, the MACD histogram at zero suggests momentum remains fragile and susceptible to negative catalysts.

Should You Buy WLD? Entry Strategy For traders considering WLD positions, the current price around $0.58 offers a strategic entry point near the pivot level. Conservative buyers should wait for a clear break above $0.60 with volume confirmation before establishing long positions targeting $0.65.

Risk management suggests implementing stop-losses below $0.56 to limit downside exposure. The Average True Range of $0.04 indicates typical daily volatility, allowing for appropriate position sizing based on individual risk tolerance.

Swing traders might consider accumulating positions between $0.56-$0.58 range while monitoring for breakout signals above $0.60. The 24-hour trading volume of $4.4 million provides adequate liquidity for most position sizes.

Conclusion The WLD price prediction for the coming weeks suggests a consolidation phase within the $0.56-$0.65 range, with technical indicators supporting potential upside toward Bollinger Band resistance. While the neutral RSI and converging MACD provide flexibility for directional movement, the proximity to key resistance at $0.60 makes this level critical for determining Worldcoin's next major move.

Traders should monitor volume patterns and RSI momentum for confirmation of any breakout attempt. The Worldcoin forecast remains cautiously optimistic in the short term, though broader market conditions will likely influence the ultimate direction.

Cryptocurrency price predictions involve significant risk and should not constitute financial advice. Always conduct thorough research and consider consulting with financial professionals before making investment decisions.

Image source: Shutterstock

wld price analysis wld price prediction

Tony Kim Jan 11, 2026 13:37

SHIB price prediction shows potential recovery to $0.0000082-$0.000010 range as recent analyst forecasts align with neutral RSI and oversold recovery signals targeting 15-17% upside.

Shiba Inu (SHIB) is displaying mixed signals as we enter the second week of January 2026, with the meme coin trading at $0.00000867 according to current market data. Recent analyst forecasts and technical indicators suggest a potential recovery phase ahead, despite bearish momentum signals in the short term.

SHIB Price Prediction Summary • Short-term target (1 week): $0.0000075-$0.0000079 • Medium-term forecast (1 month): $0.0000082-$0.000010 range
• Bullish breakout level: $0.00001019 • Critical support: $0.00000859

What Crypto Analysts Are Saying About Shiba Inu While specific analyst predictions from the past 24 hours are limited, recent forecasts from established crypto news platforms provide valuable insight into SHIB's trajectory. According to MEXC News from January 6, 2026, "The SHIB price prediction for early January 2026 targets the $0.00001019 level with medium confidence, representing 17-20% upside potential."

Blockchain.News analysis from January 5 suggests that "SHIB faces short-term consolidation around $0.0000075-$0.0000079 with medium-term recovery potential to $0.0000082-$0.0000095 as oversold conditions and ecosystem developments support bullish reversal."

Watcher.Guru's conservative modeling from January 4 indicates that "Conservative models for the Shiba Inu price forecast place SHIB around $0.000007 in January, with moderate scenarios projecting $0.000009-$0.000010 through various major recovery signals from oversold levels."

SHIB Technical Analysis Breakdown Current technical indicators present a mixed but cautiously optimistic picture for the Shiba Inu forecast. The RSI reading of 58.72 places SHIB in neutral territory, suggesting neither overbought nor oversold conditions - a healthy position for potential upward movement.

The MACD histogram shows bearish momentum at 0.0000, indicating short-term selling pressure. However, this bearish signal may be losing steam as the token approaches potential support levels. The Bollinger Band position of 0.7219 suggests SHIB is trading closer to the upper band, indicating some upward pressure within the current range.

With a 24-hour trading volume of $4,007,644 on Binance and a modest decline of 0.12%, SHIB is showing relatively stable trading activity. The daily trading range between $0.00000859 and $0.00000872 establishes clear short-term support and resistance levels.

Shiba Inu Price Targets: Bull vs Bear Case Bullish Scenario The bullish case for this SHIB price prediction centers on the convergence of analyst targets and technical recovery signals. A break above the immediate resistance at $0.00000872 could trigger momentum toward the $0.0000082-$0.0000095 range identified by recent analysis.

The ultimate bullish target remains the $0.00001019 level, which would represent approximately 17-20% upside from current levels. Technical confirmation would require sustained volume above 5 million and RSI breaking above 65.

Bearish Scenario The bearish scenario involves a break below the critical support at $0.00000859, which could lead to a test of lower levels around $0.000007 as suggested in conservative forecasts. The current MACD bearish momentum supports this downside risk.

Key risk factors include broader crypto market weakness, reduced meme coin interest, and failure to maintain current support levels during low-volume trading periods.

Should You Buy SHIB? Entry Strategy Based on current technical levels and analyst forecasts, potential entry points for SHIB include the $0.0000075-$0.0000079 consolidation zone identified in recent analysis. This aligns with near-term support levels and provides a favorable risk-reward ratio.

Suggested stop-loss placement below $0.000007 would limit downside exposure while allowing for the projected recovery to the $0.0000082-$0.000010 range. Risk management should include position sizing no more than 2-3% of total portfolio given the volatile nature of meme coins.

Conclusion This Shiba Inu forecast suggests cautious optimism for the coming weeks, with multiple analyst predictions converging on recovery targets between $0.0000082-$0.000010. While short-term bearish momentum exists, the neutral RSI and analyst confidence in oversold recovery provide a foundation for potential upside.

Investors should monitor the critical $0.00000859 support level and watch for volume confirmation above 5 million for bullish validation. The 17-20% upside potential to $0.00001019 remains achievable based on current technical and fundamental analysis.

Disclaimer: Cryptocurrency price predictions are speculative and subject to high volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and risk assessment before making investment decisions.

Image source: Shutterstock

shib price analysis shib price prediction

Timothy Morano Jan 11, 2026 13:42

Toncoin consolidates around $1.76 as analysts maintain $2.40 targets by January 12, while technical indicators show neutral RSI at 54.99 and key resistance at $1.82.

TON Price Prediction Summary • Short-term target (1 week): $1.82-$2.40 • Medium-term forecast (1 month): $1.70-$2.50 range
• Bullish breakout level: $1.82 • Critical support: $1.70

What Crypto Analysts Are Saying About Toncoin While specific analyst predictions from crypto Twitter remain limited in the last 24 hours, recent forecasting data provides clear targets for Toncoin's near-term trajectory.

According to CoinCodex analysis from January 7, 2026, "Toncoin is expected to reach a price of $2.40 by Jan 12, 2026." This represents a potential 36% upside from current levels around $1.76.

Blockchain.News reported on January 10, 2026, that "TON shows mixed signals as analysts eye $2.40 targets while technical indicators suggest consolidation around $1.76 support levels." This Toncoin forecast aligns with current price action showing consolidation within a defined range.

According to on-chain data, Toncoin maintains healthy trading volumes at $6.19 million on Binance spot markets, suggesting sustained institutional interest despite the recent 1.46% daily decline.

TON Technical Analysis Breakdown Toncoin's current technical setup reveals a neutral to slightly bearish short-term outlook. The RSI reading of 54.99 positions TON in neutral territory, avoiding both overbought and oversold conditions that could trigger immediate reversals.

The MACD histogram at 0.0000 indicates bearish momentum, though the proximity to the signal line suggests this trend could reverse quickly. Toncoin's position within the Bollinger Bands shows a %B reading of 0.60, indicating price trading closer to the upper band than lower support.

Moving average analysis reveals mixed signals for this TON price prediction. While Toncoin trades above the 20-day SMA ($1.71) and 50-day SMA ($1.62), it remains significantly below the 200-day SMA at $2.50. The EMA 12 at $1.77 provides immediate resistance, while the EMA 26 at $1.71 offers dynamic support.

Key resistance levels emerge at $1.79 (immediate) and $1.82 (strong resistance), with support established at $1.73 (immediate) and $1.70 (strong support). The daily ATR of $0.10 suggests moderate volatility, providing clear risk parameters for position sizing.

Toncoin Price Targets: Bull vs Bear Case Bullish Scenario A successful break above the $1.82 resistance level could trigger momentum toward the $2.40 target cited by multiple analysts. This Toncoin forecast scenario requires volume confirmation above 7 million daily and RSI pushing toward 60-65 territory.

The bullish path targets the upper Bollinger Band at $1.98 as an intermediate level before challenging the 200-day SMA resistance at $2.50. A break above this psychological level could extend gains toward $2.80-$3.00, representing the next major resistance cluster.

Bearish Scenario Failure to hold the $1.73 immediate support could lead to a test of strong support at $1.70. A break below this level would target the lower Bollinger Band at $1.43, representing a 19% downside risk from current levels.

The bearish TON price prediction scenario would be confirmed by RSI falling below 45 and sustained selling pressure exceeding 8 million in daily volume. Additional downside targets include the psychological $1.50 level and potential retest of yearly lows.

Should You Buy TON? Entry Strategy Current levels around $1.76 offer a reasonable entry point for this Toncoin forecast, particularly given the proximity to key support levels. Conservative buyers should wait for a pullback to $1.73-$1.70 to improve risk-reward ratios.

Aggressive traders can enter on a confirmed break above $1.82 with volume, targeting the $2.40 analyst consensus. Stop-loss levels should be placed below $1.70 to limit downside risk to approximately 3-4% from current entry points.

Position sizing should account for the $0.10 daily ATR, suggesting natural volatility of 5-6% in either direction. This TON price prediction supports allocation of 2-3% of portfolio risk capital given the technical setup.

Conclusion The TON price prediction for the next week suggests a potential move toward $2.40 targets, supported by analyst forecasts and technical consolidation patterns. However, the neutral RSI and bearish MACD momentum require careful monitoring of volume confirmation above key resistance levels.

This Toncoin forecast carries moderate confidence given the convergence of analyst targets around $2.40 and established support levels near $1.70. Traders should remain disciplined with risk management, as cryptocurrency markets can experience rapid volatility that invalidates technical projections.

Disclaimer: This TON price prediction is for educational purposes only. Cryptocurrency investments carry substantial risk, and past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before trading.

Image source: Shutterstock

ton price analysis ton price prediction

Sun, 11/01/2026 - 12:46

Solana is seeing a massive surge in open interest that might push its volatility to new heights sooner than anticipated.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Even after months of significant drawdowns, the market is once again willing to take risk on SOL as evidenced by the fact that Solana crossed the $8 billion open interest threshold. At this level, open interest indicates that traders are actively positioning rather than passively watching and leverage has returned to the system.

Activity around SolanaSolana is not currently a forgotten asset based only on that. In terms of price, SOL is not trending but is still technically recovering. The price found a base in the low $120s and has been steadily rising since the steep sell-off from the $200+ area. The rebound appears controlled rather than exuberant.

SOL/USDT Chart by TradingViewThe 100 and 200-day EMAs are still sloping downward, and SOL is trading below its main long-term moving averages. The short-term structure is improving, but the overall trend remains bearish to neutral for the time being. Here, it matters where this open interest is developing.

HOT Stories

Futures positioningFutures positioning has shifted significantly in favor of longs, especially around whales. There are two sides to that. On the one hand, it conveys the belief that SOL's ecosystem activity and long-term story are undervalued. However, if the price is unable to maintain important support zones between $130 and $135, there is a greater chance of abrupt liquidations.

You Might Also Like

Data from on-chain and flow indicates mixed but stable conditions. Spot volumes are still low in comparison to previous cycle highs, indicating that derivatives rather than organic spot demand are still the primary driver of this shift. Nonetheless, the lack of aggressive spot selling is encouraging since sellers are not hurrying to sell at these prices.

Volatility is going to be the main risk. Even slight price changes can cause exaggerated reactions when open interest is this high. Fake breakouts or abrupt works in either direction could easily occur on weekends and during low-liquidity sessions. Instead of a clean trend continuation, investors should anticipate instability.

A wider trend reversal may be supported by this open interest buildup if SOL can recover and stay above the mid-$140s while controlling funding rates. Otherwise, it would not be shocking to see a flush toward lower support. In any case, Solana is obviously back on traders' radar, and that in and of itself alters the game.

Related articles

Jessie A Ellis Jan 11, 2026 13:54

CRV price prediction shows bullish momentum building with analyst targets of $0.55-$0.72. Curve forecast indicates potential 33-75% upside from current $0.40 levels.

Curve DAO Token (CRV) is trading at $0.403 as of January 11, 2026, showing resilience despite a minor 0.03% daily decline. Recent analyst predictions and technical indicators suggest significant upside potential for the DeFi governance token in the coming weeks.

CRV Price Prediction Summary • Short-term target (1 week): $0.44 • Medium-term forecast (1 month): $0.55-$0.72 range • Bullish breakout level: $0.45 • Critical support: $0.39

What Crypto Analysts Are Saying About Curve Recent analyst sentiment has turned increasingly bullish on CRV's prospects. According to blockchain analyst Iris Coleman from January 5th, "CRV price prediction shows bullish momentum building with MACD histogram positive at 0.0071. Curve forecast targets $0.55-$0.72 medium-term with immediate resistance at $0.44."

Lawrence Jengar echoed this optimism on January 6th, stating "CRV price prediction shows bullish momentum with MACD histogram at 0.0076. Curve forecast targets $0.55-$0.76 if $0.45 resistance breaks in medium term."

Most recently, Jessie A Ellis reinforced these predictions on January 10th, noting "CRV price prediction shows bullish momentum building with analyst targets of $0.55-$0.72. Curve forecast indicates potential 33-75% upside from current $0.41 levels."

The consensus among analysts points to a potential breakout scenario once CRV overcomes the $0.44-$0.45 resistance zone.

CRV Technical Analysis Breakdown Current technical indicators present a mixed but cautiously optimistic picture for CRV. The token is trading at $0.40, positioned exactly at its 20-day Simple Moving Average (SMA), indicating equilibrium between buyers and sellers.

The RSI reading of 51.23 places CRV in neutral territory, suggesting neither overbought nor oversold conditions. This neutral positioning often precedes significant directional moves, particularly when combined with other technical factors.

The MACD histogram currently sits at 0.0000, indicating bearish momentum has stalled. However, the main MACD line at 0.0064 remains above the signal line, suggesting underlying bullish pressure may be building.

Bollinger Band analysis shows CRV trading at 0.55 of the band range, positioned above the middle band at $0.40 but below the upper band at $0.44. This positioning indicates moderate bullish momentum with room for upward expansion.

Key resistance levels are clearly defined at $0.41 (immediate) and $0.42 (strong), while support levels sit at $0.40 (immediate) and $0.39 (strong). The Average True Range of $0.02 indicates moderate volatility, providing reasonable profit opportunities for swing traders.

Curve Price Targets: Bull vs Bear Case Bullish Scenario In the bullish scenario, CRV breaks above the $0.42 resistance level with strong volume confirmation. This would likely trigger a move toward the $0.44 level, representing the upper Bollinger Band and a crucial psychological resistance.

A sustained break above $0.45 would validate analyst predictions and open the path to $0.55-$0.72 targets. The 75% upside potential to $0.72 appears achievable if broader DeFi sentiment remains positive and Curve's protocol metrics continue improving.

Technical confirmation would come from RSI breaking above 60, MACD histogram turning positive, and volume exceeding the recent daily average of $2.67 million.

Bearish Scenario The bearish case emerges if CRV fails to hold the $0.40 support level. A breakdown below this crucial level could trigger selling pressure toward the $0.39 strong support zone.

Further deterioration below $0.39 would invalidate the bullish thesis and potentially lead to a test of the lower Bollinger Band at $0.36. This would represent a 10% decline from current levels.

Risk factors include broader cryptocurrency market weakness, DeFi sector rotation, or negative developments in Curve's ecosystem.

Should You Buy CRV? Entry Strategy For potential buyers, the current $0.40 level presents an interesting risk-reward setup. Conservative investors might wait for a pullback to $0.39 support for better entry positioning.

Aggressive traders could consider entries above $0.42 on strong volume, confirming the breakout scenario. A stop-loss below $0.38 would limit downside risk to approximately 5%.

Position sizing should reflect the moderate volatility indicated by the $0.02 Average True Range. Risk management remains crucial given the speculative nature of cryptocurrency markets.

Conclusion The CRV price prediction outlook appears moderately bullish based on analyst consensus and technical positioning. The $0.55-$0.72 targets represent realistic medium-term objectives if resistance levels are overcome with conviction.

Current technical indicators suggest CRV is at a critical juncture, with the next few trading sessions likely determining whether the token breaks higher or retreats to test support levels.

Disclaimer: Cryptocurrency price predictions are highly speculative and involve substantial risk. Past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

crv price analysis crv price prediction

Journalist

Posted: January 11, 2026

Official Trump [TRUMP] memecoin remained inside a descending channel after topping near $9.5 two months ago. Price attempts to reclaim $5.6, fails, leaving the memecoin range-bound.

At press time, TRUMP traded near $5.4 after a modest daily pullback.

That stagnation appeared to pressure long-term holders. Several whales exited positions after months of inactivity.

TRUMP whales exit after deep drawdowns TRUMP memecoin has recorded a significant shift in sentiment, especially from large holders who jumped to accumulate early last year. 

In fact, whales have not made any significant purchases since October 2025, when whales recorded an accumulation for seven consecutive days. In recent days, TRUMP has recorded no whale buy activity for six consecutive days, as per the Whale Buy Activity Indicator on Trading View.

Source: TradingView

Instead, whales have been consistently selling. Looking at the Whale Trend Analysis metric on Tradingview, whales have sold throughout the past 11 days. 

Arkham data captured one such whale activity. According to Arkham, a whale sold his entire Trump holdings after holding for 8 months. 

Source: Arkham

The whale deposited 437k TRUMP tokens worth $2.35 million into Binance. These tokens were purchased for $4.7 million, and with the recent sale, the whale realized $2.35 million in loss.

When whales realize losses exceeding 50%, it often reflects eroding conviction rather than tactical rotation. That behavior suggested capital stepped aside instead of repositioning.

Momentum weakens as sellers dominate Selling pressure showed up across momentum indicators.

The Directional Movement Index showed a negative index near 30, above the positive index near 21. That configuration reflected strengthening downside control.

Source: TradingView

On top of that, TRUMP remained below the 50, 100, and 200 EMA levels. Price structure continued to favor sellers.

If distribution persists without matching demand, TRUMP could revisit the 20 EMA near $5.2. A breakdown there could expose the $5.0 zone, with downside risk toward $4.6.

For trend reversal signals, bulls would need a decisive reclaim of the 50 EMA near $5.5. Without that shift, rallies may continue to face supply.

Final Thoughts TRUMP’s price action reflected more than short-term volatility; it mirrored fading conviction among large holders. Without renewed accumulation or a reclaim of key EMAs, downside risk may continue to define near-term sentiment.

According to TradingView data, big holders on Bitfinex have been trimming long positions after a late-December peak of 73,000 BTC. The move follows a broader drop in whale holdings of roughly 220,000 BTC during 2025, a change that has analysts and traders parsing what comes next.

Price action has been steady. Bitcoin has been moving inside a tight range around $88,000 to $92,000 while the market seeks direction.

Whale Moves And Historical Patterns Based on reports, some traders see this as a classic unwind pattern that precedes price gains. In early 2025, a similar fall in long positions coincided with Bitcoin slipping under $74k then staging a sharp rebound.

That past recovery climbed to about $112k in 43 days after positions were flushed. MartyParty, a commentator on X, pointed to that episode when noting Bitfinex whales were “aggressively closing $BTC longs,” a behavior that has in the past been followed by big swings.

Bitfinex whales are aggressively closing $BTC longs, a signal that historically precedes massive volatility. Last time this “unwind” happened in early 2025, Bitcoin was stalling at $74k.

This precedes the Wyckoff Spring. See charts below.

The flush cleared leverage and ignited… pic.twitter.com/2qfmH2eliJ

— MartyParty (@martypartymusic) January 10, 2026

Market Breadth And Investor Mix Reports have disclosed that on-chain tracker CryptoQuant finds overall whale holdings fell by over 200,000 BTC across the year, while smaller investors have increased exposure. This shift is being read by some as a sign that ownership is broadening.

If more participants hold coins, price moves can be supported by a wider base of buyers. That does not guarantee higher prices, but it does change the way risk spreads through the market.

BTCUSD now trading at $90,619. Chart: TradingView Price Range And Resistance Levels Traders are watching a near-term ceiling around $94,000 that has capped several rallies. Bitcoin currently sits near $91.5k. A sustained break above that $94,000 level with volume would be a stronger confirmation for bulls. On the flip side, a failure to move higher could see the range widen to the downside, especially if funding costs rise or if liquidations pick up.

Fractal Targets And Caution Some analysts are using past patterns to project targets. Based on reports, one scenario maps a repeat of the spring-and-rally sequence, aiming at $135k or more if history repeats closely enough.

That view depends on similar market conditions lining up, which is not certain. Whales are not a single, unified actor; different groups can close positions for different reasons, and some trades are used as hedges rather than bets on price direction.

Volume, funding rates, and net positioning on major derivatives platforms will matter. A clean breakout above $94,000 with rising spot demand would support the bullish case.

Conversely, rising selling pressure at that level could keep Bitcoin confined to the $88,000–$92,000 band until a new catalyst appears. The current action looks like a setup in progress — one that could lead to sharp moves once traders decide on direction.

Featured image from Unsplash, chart from TradingView

Bitmine’s latest 86,400 ETH staking transfer landed as Ethereum charts began flashing a clear shift in market structure. Together, on chain data and multi timeframe technical setups now point to growing momentum across both institutional flows and price action.

Bitmine sends 86,400 ETH to Ethereum staking deposit contract, post claimsBitmine sent 86,400 ETH to Ethereum’s staking deposit contract about eight hours before a post from Crypto Patel on X highlighted the transfers, pointing to fresh on chain deposits tied to Fundstrat’s Tom Lee. The screenshot of the transfers list shows four separate deposits from Bitmine labeled addresses to a “BatchDeposit” destination, with values of 23.04K ETH, 21.12K ETH, 19.2K ETH, and 23.04K ETH, which add up to 86,400 ETH.

Bitmine Ethereum Staking Transfers. Source: Crypto Patel/X

The same transfer records show estimated dollar values near $71.02 million, $65.1 million, $59.18 million, and $71.02 million, totaling about $266.3 million for the batch. The “BatchDeposit” label appears alongside a shortened contract identifier, indicating the deposits routed through a batching method rather than a single transaction.

Crypto Patel’s post said Bitmine has now staked 1,080,512 ETH worth about $3.33 billion. The post also claimed Bitmine holds 4.144 million ETH, or about 3.43% of Ethereum’s total supply, valued at roughly $12.80 billion.

Ethereum breaks out of falling channel as chart signals higher price zoneEthereum broke above a long running falling channel on the daily chart, according to a technical setup shared by Crypto King on X, pointing to a shift in short term price structure. The chart, based on ETH U.S. dollar data from Binance, shows price moving out of a downward parallel channel that had guided trading since late 2025. After the breakout, Ethereum pulled back slightly but held above the former channel boundary, a move that often marks confirmation rather than rejection.

Ethereum Downtrend Channel Breakout Chart. Source: Crypto King/X

The chart also highlights a completed falling wedge pattern inside the broader downtrend. As price compressed toward the lower end of the structure, volatility narrowed before the upside break. Fibonacci levels drawn on the chart place the 0.618 retracement near the mid channel area, which Ethereum has now reclaimed. Price trades around $3,090 on the latest candle, well above the recent range lows near $2,600.

Crypto King said consolidation appears complete and projected an upside target above $4,400 if the breakout holds. The forward path drawn on the chart shows a stepped advance, with an initial push toward the mid $3,600 area before a continuation higher. While the projection remains technical, the chart reflects a clear change in trend direction after months of lower highs and lower lows.

Ethereum weekly chart points to higher cycle targets based on long term structureMeanwhile, Ethereum’s weekly chart suggests room for further upside in the current market cycle, according to technical analysis shared by the account Freedom By 40 on X. The chart, based on Ethereum U.S. dollar data from Bitstamp, outlines a broader rising structure that has remained intact since the 2022 market low. Price recently traded near $3,233, holding above a long term ascending trendline that has supported higher lows over multiple years.

Ethereum Weekly Cycle Projection Chart. Source: Freedom By 40/X

The chart applies Elliott Wave labeling and Fibonacci extensions to frame potential cycle targets. Markings show a completed corrective phase followed by a renewed impulse structure, with projected extensions ranging from the 1.0 level near $6,448 to higher bands above $9,000. The 1.236 and 1.38 Fibonacci extensions are also highlighted, placing longer term reference zones near $9,270 and $11,567, respectively. The analysis notes that even a move toward the lower extension would remain consistent with prior cycle behavior.

Freedom By 40 said a minimum target around $6,400 would still fall within a conservative range for the cycle, based on the technical setup shown. The chart compares the current structure with the previous cycle’s peak, marked as the last Elliott Wave all time high, and shows Ethereum continuing to respect a rising diagonal support. While the projections remain technical, the weekly structure reflects sustained higher highs and higher lows, keeping the broader uptrend intact.

XRP trades near $2.09 as banks and Ripple leaders outline bold 2026 forecasts tied to ETFs, regulation, and institutional adoption.

Cover image via www.freepik.com Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The crypto markets may look calm on the surface, but this weekend saw three major shocks: XRP had just 1.16% of its entire market cap locked inside ETFs, a SHIB mega-whale pulled nearly 2 trillion tokens straight off Coinbase Prime, and Vitalik Buterin casually posted what could be the blueprint for the next stablecoin revolution.

TL;DRXRP ETF net assets hit $1.47 billion and now make up 1.16% of the total market cap.One Shiba Inu (SHIB) address is worth 1.92 trillion tokens on Coinbase.Vitalik Buterin shares his three-step plan to fix stablecoins.XRP ETFs now control over 1.16% of marketXRP just hit a pretty surprising milestone, with $1.47 billion now sitting locked inside U.S.-based spot ETFs, as per SoSoValue. That is not just a nice round number — it is 1.16% of XRP's full market cap, wrapped up in regulated wrappers and taken off the playing field.

That does not mean the tokens are gone or burned. These XRP are parked, passive and — at least for now — off-limits to daily price action.

HOT Stories

ETF flows like this tend to fly under the radar — until they don't. That $1.47 billion is money that has been slowly but surely changing the market's dynamics for XRP. If people keep buying into the ETF, it will create a "price magnet" around the net asset zone, which right now is about the $2.00-$2.10 XRP range.

Source: SoSoValueIf inflows go past $1.6 billion in Q1, expect XRP to start acting more like an ETF-backed commodity and less like a retail-driven altcoin. This means more muted reactions to news, more compression around the $2.30 zone and potentially fewer shakeouts.

Weekly flows show that the momentum has slowed down since the flood of late 2025. After a $243 million week in mid-November, this past week only added $38 million. But the direction has not changed, it has just slowed down. That is the most important thing.

This kind of profile might explain why XRP volatility has been dampened lately. The same buyers who were once fueling wicks are now holding wrapped exposure through XRPC (Canary), XRPZ (Franklin) and others. And they are not selling the dip — they are not even touching the chart.

You Might Also Like

Unknown Shiba Inu whale pulls 1.9 trillion tokens from CoinbaseOne wallet is eating Shiba Inu coins like it is on a discount. Address 0xb57a394 pulled in 1,923,043,775,311 SHIB over the past two weeks — yes, that's trillion with a T. All of it came straight from Coinbase Prime.

Arkham has had at least 15 transfers since late December. Some were massive — 214 billion at a time. Others were small scoops, like 5.9 billion SHIB. What's the total value? It is just over $16 million so far, and it is all still sitting at that address.

Just a guess: This is not some meme trader trying to pull a fast move. It looks like treasury positioning. It could be for a project using Shibarium or for some ecosystem play that has not been revealed yet.

In the meantime, the price of the Shiba Inu coin is stuck right under $0.000009, trying to hold the line. It briefly spiked up to $0.00000950 last week, but then lost steam. It is currently at around $0.00000867 on Binance.

Source: ArkhamIf that $0.000009 flips into support, bulls will probably go for $0.00001102 next. If it fails again, then $0.00000699 is the line in the sand. For now, this whale's steady buying is the most optimistic thing SHIB has going for it.

What's interesting is that this wallet is not just reacting to the price — it is leading the charge. The accumulation started before the breakout attempt. That suggests it was not chasing momentum. It was loading ahead of something.

This is the kind of behavior you would expect before a staking launch, L2 incentive unlock or liquidity pool announcement. If SHIB gets any utility catalyst this month, this wallet will be the canary that called it early.

Vitalik Buterin thinks most stablecoins are built wrong, but he has solutionVitalik Buterin dropped a casual post this weekend, but it reads like a big-picture manifesto. To sum it up, decentralized stablecoins are not quite up to par. And it is not just about the tech — it is about design flaws that no one is fixing.

Here is what the Ethereum creator laid out:

Stop pegging everything to the dollar. Use an index that makes more sense for crypto.Make oracles truly decentralized and hard to manipulate — no backdoors for whales.Fix the yield problem. If staking rewards compete with your stablecoin's stability, your system is already broken.That third point hits hardest right now. In most stablecoin systems, capital gets split — some gets locked into the stablecoin's mechanism, but a growing portion chases higher yield elsewhere. This makes the peg's collateral base weaker and forces projects to offer higher rewards just to stay competitive.

Buterin's take: Competition for yield is killing decentralization. You cannot offer 20% APY and expect stable behavior. He did not mention any names, but it is pretty clear he is talking about protocols like Frax, Liquity and maybe even MakerDAO with their DAI.

We need better decentralized stablecoins. IMO three problems:

1. Ideally figure out an index to track that's better than USD price
2. Oracle design that's decentralized and is not capturable with a large pool of money
3. Solve the problem that staking yield is competition…

— vitalik.eth (@VitalikButerin) January 11, 2026 Basically, Buterin is pushing for a more neutral way of measuring things that can be used in the ecosystem. Something that is not tied to Fed interest rates or USD credibility.

Do not expect a new coin from Vitalik Buterin, but do expect a wave of discussion. If one of the major Ethereum builders takes this thread seriously, it could trigger a new design cycle — likely on L2s where experimentation is faster.

If any new "index-stable" shows up in Q1, especially with Oracle innovation, it will probably be linked to this post.

What to watch in crypto heading into the weekThe crypto market is not too exciting right now, but things are changing behind the scenes. Wrapped XRP is not going back into circulation anytime soon. There is a trillion SHIB sitting in one place. Ethereum might be the quiet force behind a new wave of stablecoins — this time built with more brains than branding.

Key levels to keep an eye on:

Shiba Inu (SHIB): $0.000009 is the level to flip. Keep an eye on $0.00001102 above and $0.00000699 below.

XRP: The ETF zone support is holding stable at around $2-$2.1. The mid-band is currently at $1.89.

Ethereum: No changes yet at above $3,000, but any dev team teasing an "index-stable" is probably taking notes from Vitalik Buterin's thread.

You Might Also Like

Crypto markets may be quietly turning a corner, according to analyst Ran Neuner, but he says this is not the time for blind optimism.

Neuner says he is “cautiously bullish”, meaning the signs look better than before, but the market still has something important to prove.

Why He’s Feeling Better Than BeforeNeuner pointed to a key move that happened right around New Year’s. Bitcoin broke above its short-term downtrend and climbed back above its 50-day moving average, a level many traders watch closely.

What made this move more convincing was the follow-through. Bitcoin didn’t just jump above the level, it came back down, tested it, and held. Neuner says that usually shows strength, not weakness.

Even more interesting, the same thing happened across other major coins. Ethereum, Solana, and XRP have all moved back above their 50-day averages too.

“That tells you this isn’t just one coin moving,” Neuner explained. “It’s the whole market trying to recover.”

U.S. Buyers Are BackAnother signal catching attention is the return of the Coinbase premium. This happens when Bitcoin trades slightly higher on Coinbase compared to other exchanges, showing stronger demand from U.S. investors.

Neuner says this matters because many past rallies started when American buyers stepped back in first.

Simply put, more buyers than sellers are showing up again.

The Market Is Acting HealthierNeuner also opened up about changes in market structure. Prices are now forming higher highs and higher lows, which is often how recoveries begin.

At the same time, altcoins have started outperforming Bitcoin, and Bitcoin dominance has slipped a bit. That usually means traders are becoming more confident and willing to take risk again.

“These are early signs,” Neuner said, “but they are signs.”

The Level That Decides EverythingDespite all the positives, Neuner says Bitcoin is heading toward a make-or-break moment.

The 200-day moving average, which sits around $107,000, is the next major hurdle. In strong bull markets, Bitcoin pushes above this level and keeps going. In weaker markets, price rallies up to it, gets rejected, and then drops again.

Neuner warned that past cycles have seen this exact setup turn into a fake recovery that pulled people back in before the market fell lower.

A Warning From the Weekly ChartZooming out even more, Neuner pointed to the weekly chart, where Bitcoin has dropped below its 50-week moving average. Historically, that level has acted as strong support during bull markets.

In earlier cycles, once Bitcoin lost that level, price often bounced back to it, failed to reclaim it, and then slid toward the 200-week moving average, which now sits near $60,000.

That would be the bearish scenario.

So… Bull Market or Fake Bounce?Neuner says the market is standing at a crossroads.

If Bitcoin breaks above major resistance and holds it, this could be the next leg of the bull market. If it fails, the recent rally could end up being just a pause before more downside.

“For now, things look better,” he said. “But the next move will tell us the real story.”

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Tether has come under renewed scrutiny after reports linked Iran’s Islamic Revolutionary Guard Corps to large-scale crypto movements using USDT, raising questions about enforcement versus exposure.

Investigative reporting citing blockchain analytics firm TRM Labs said IRGC-linked entities moved close to $1 billion in cryptocurrency since early 2023, largely through USDT on the Tron network. The activity reportedly ran through two UK-registered exchanges, Zedcex and Zedxion, which investigators say were used to bypass international sanctions.

The reported figure refers to transaction volume, not assets seized or frozen. However, headlines and social media posts quickly framed the finding as “Tether freezing $1 billion,” prompting confusion across crypto markets and policy circles.

Tether has repeatedly said it cooperates with law enforcement and complies with sanctions requests. The company maintains the ability to freeze USDT at the address level when wallets are formally sanctioned or flagged by authorities.

What Investigators Found in the IRGC-linked FlowsTRM Labs said it identified IRGC-linked activity by tracking deposits, withdrawals, and wallet infrastructure tied to the two exchanges. According to the analysis, IRGC-associated crypto flows totaled about $24 million in 2023, surged to roughly $619 million in 2024, and reached around $410 million in 2025.

Most of the funds moved in USDT, reflecting the stablecoin’s liquidity and acceptance across offshore trading venues. Investigators said Tron’s low transaction fees and fast settlement made it the preferred network for these transfers.

The findings were shared with journalists and cited as part of broader reporting on how sanctioned actors continue to access crypto rails despite global compliance frameworks.

What Tether Actually FrozeSeparately, documented enforcement actions show far smaller amounts were frozen. In September 2025, Israel’s National Bureau for Counter Terror Financing published a list of 187 wallet addresses it linked to IRGC activity.

Following that designation, Tether blacklisted 39 of those addresses, freezing about $1.5 million in USDT held in those wallets at the time, according to blockchain intelligence firm Elliptic.

That distinction matters. The $1 billion figure reflects cumulative crypto movement, while the freeze involved only balances present in sanctioned wallets when action occurred. Tether has not confirmed freezing anything close to $1 billion in a single enforcement move.

The episode highlights the gap between tracking illicit crypto flows and actually seizing assets, as regulators and stablecoin issuers continue to face pressure over sanctions enforcement in global crypto markets.

MP Materials' strategic position in the U.S. rare earth supply chain can position it as a beneficiary of the AI infrastructure buildout.

The next market cycle is unlikely to be solely led by artificial intelligence (AI)-powered chips and software stocks alone. Instead, industrial companies that supply strategic materials, expand power availability and grid capacity, and deliver power and thermal management solutions are becoming critical to addressing the real-world constraints in the AI infrastructure buildout.

As investors shift from purely technology-driven narratives to companies that control scarce physical inputs required for AI infrastructure, a few industrial material suppliers could rise to prominence. Here's why MP Materials (MP +1.44%) fits the bill.

Image source: Getty Images.

What MP Materials does MP Materials has evolved from being a rare earth mining and processing player to a vertically integrated company, encompassing upstream mining and concentrates, midstream separation and refining of rare earth metals (17 metals used to make magnets), and downstream production of high-performance permanent magnets. As the operator of Mountain Pass, the only major rare-earth mining and processing site in the U.S., the company plays a critical role in building a domestic rare-earth supply chain required for the production of high-performance magnets used in electric vehicles, defense systems, and across AI data centers and in semiconductor manufacturing processes.

Today's Change

(

1.44

%) $

0.88

Current Price

$

61.94

Neodymium-praseodymium (NdPr) oxide is one of MP Materials' most prominent and economically significant products, used in high-performance magnets.

In the third quarter, the company's NdPr oxide production soared 51% year over year to 721 metric tons, while the output of overall rare earth oxides (REOs, including NdPr) reached a record 13,254 metric tons. The company is focused on achieving its goal of 60,000 metric tons of annual output. The rapid expansion of production capacity may lead to further growth in the downstream magnet business.

In July 2025, MP Materials secured a public-private partnership with the U.S. Department of Defense, which includes a 10-year price floor protection agreement (PPA) at $110 per kilogram for NdPr products. Active as of Oct. 1, 2025, this partnership reduces downside risk for the company, while also improving the earnings visibility and predictability of cash flows for NdPr products compared to those of unprotected commodities. Subsequently, the company expects to return to positive earnings per share (EPS) in the fourth quarter, in line with the analysts' consensus estimate of $0.07.

Apple's $500 million commitment to MP Materials, which includes long-term purchases of American-made rare-earth magnets and the buildout of a dedicated rare-earth recycling line, has further improved demand visibility and reduced the downside risk for MP's downstream magnetics business. The company has already received a $40 million prepayment from Apple for producing magnets from recycled rare earth materials, and expects a total of $200 million tied to the buildout of a recycled magnet production facility.

MP Materials is also working with General Motors on the commercial-scale qualification (formal technical and commercial approval process) of permanent magnets, and expects magnet sales to GM to commence in the second half of 2026.

MP Materials' shares have gained over 242% in the past year. Yet considering its critical role in the rare-earth supply chain and improving earnings visibility, the company is well-positioned to soar even higher in the coming months.

Manali Pradhan, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple. The Motley Fool recommends General Motors and MP Materials. The Motley Fool has a disclosure policy.

AST SpaceMobile (ASTS +7.58%) stock soared in 2025. The 244% gain came as investors began to get excited about the prospect of AST tapping into a massive potential market of smartphone users who might want direct satellite internet access.

That excitement grew in December for a good reason, and shares surged 29.2%, according to data provided by S&P Global Market Intelligence.

Image source: Getty Images.

A defining moment for AST SpaceMobile AST is developing a low Earth orbit (LEO) network aimed at delivering broadband connectivity to regular smartphones. LEO positions the satellites just a few hundred miles above the Earth, which helps minimize delays that have traditionally plagued older satellite systems placed in higher orbits.

The successful orbital launch of the company's BlueBird 6 satellite array in December was what AST SpaceMobile founder and CEO Abel Avellan called a "breakthrough moment." BlueBird 6 is the largest commercial communications constellation ever launched into low Earth orbit. It has 10 times the data capacity of the existing satellites AST already had in orbit. It will enable peak data rates that will support voice, video, and data needed for standard smartphones.

Investors view it as a significant step in the company's path to generating meaningful revenue and achieving sustained profitability, helping to send shares higher in December.

Today's Change

(

7.58

%) $

6.86

Current Price

$

97.42

Analysts are divided That successful launch helped lead Bank of America analysts to boost the firm's price target from $85 to $100 per share. With the stock recently trading near that level, a neutral rating was maintained.

The current valuation is high, however. A market capitalization of approximately $35 billion indicates that investors have already factored in the successful execution of upcoming launches, as well as the development of consumer demand for the technology. Investors wanting to get in ahead of commercialization isn't uncommon with space stocks. It takes years to build and deploy a full constellation of satellites. AST plans a rapid cadence of launches in 2026, including the next-generation BlueBird 7.

The company hopes to have between 45 and 60 satellites in orbit by the end of 2026. However, some analysts believe investors are not fully considering the risks associated with that plan. Scotiabank analyst Andres Coello recently cut his rating on AST SpaceMobile to the equivalent of a sell. His price target on the stock is just $45.60 per share. Coello believes the valuation has become unjustified, given the company's lack of a retail customer base, according to Barron's. Estimates for 2026 sales are about $270 million.

Better entry point ahead? While AST does have agreements with dozens of global mobile network operators and partnerships with some of the largest communication telecom companies, it is valued at more than 100 times that 2026 sales estimate.

Shares plunged after Coello's report last week, with the implication of a roughly 50% downside for the stock. That reaction was a reminder of how volatile the stock can be, though. While some investors may want to rush to establish a position in AST SpaceMobile, a sharp correction may occur due to the valuation. It may be wiser to wait for a more favorable entry point.

Bank of America is an advertising partner of Motley Fool Money. Howard Smith has no position in any of the stocks mentioned. The Motley Fool recommends Bank Of Nova Scotia. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - January 11, 2026) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

Investors have until January 26, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv- 11319.

Why is Alexandria Real Estate Being Sued for Securities Fraud?

Alexandria Real Estate is a real estate investment trust. Its tenants are concentrated in life science industries, such as pharmaceutical and biotechnology companies.

During the relevant period, Alexandria Real Estate touted its leasing volume and development pipeline, specifically regarding a property in Long Island City, New York, stating that leasing volume was "solid" and its pipeline was "well positioned to capture future demand when expansion needs arise."

As alleged, in truth, Alexandria Real Estate was experiencing lower occupancy rates and slower leasing activity such that it was required to take a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property.

Why did Alexandria Real Estate's Stock Drop?

On October 27, 2025, Alexandria Real Estate announced results below expectations for 3Q 2025 and cut guidance for the remainder of the fiscal year. The company attributed the results to lower occupancy rates and slower leasing activity. It also announced a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property, stating that the property was not a life science destination that could scale. Alexandria Real Estate also announced additional impairment charges that may be recognized in 4Q 25 ranging from $0 to $685 million. This news caused the price of Alexandria Real Estate stock to drop $14.93 per share, or more than 19%, from a closing price of $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025.

Click here for more information: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

What Can You Do?

If you invested in Alexandria Real Estate you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279940

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - January 11, 2026) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit.

Investors have until February 9, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Integer common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251.

Why is Integer Being Sued for Securities Fraud?

Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology ("EP") devices that map the heart's electrical activity to diagnose and treat arrhythmias.

During the relevant period, Integer repeatedly touted its EP sales growth and market position while overstating demand for its EP devices.

As alleged, in truth, demand for and revenue from Integer's EP products had fallen sharply-directly contradicting the Company's public assurances.

Why did Integer's Stock Drop?

On October 23, 2025, Integer disclosed that it lowered its 2025 sales guidance to a range between $1.840 billion and $1.854 billion, from a range between $1.850 billion and $1.876 billion, and well below analysts' estimates. The Company also revealed that it expected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. Integer also admitted that two of its EP devices experienced "slower than forecasted" adoption and that it expected the slower demand "to continue into 2026." This news caused the price of Integer stock to drop $35.22 per share, or more than 32%, from a closing price of $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025.

Click here for more information: https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit.

What Can You Do?

If you invested in Integer, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279944

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

IonQ has dominated investor attention over the past several years, but its gains could be a flash in the pan.

IonQ's (IONQ 2.00%) share price gains over the past three years have been impressive. The stock price is up more than 1,200% since the beginning of 2023, and its shareholders are no doubt hoping the good times will continue through 2026 and beyond.

But is it a good time for investors to jump on board with this popular quantum computing stock, or is it best to sit this one out? I believe investors would be better off avoiding IonQ stock for several key reasons.

Image source: Getty Images.

IonQ's stock is expensive As its name suggests, IonQ is focused on trapped-ion quantum computing, which enables quantum computers to operate at room temperature. While still in its infancy, this trapped-ion process can make reliable quantum computing easier to achieve and less difficult to use than ultra-cooled quantum computers, which is why the tech has piqued investor interest.

With IonQ's share price skyrocketing over the past several years, it should come as no surprise that the stock is expensive. But even by the standards of high-flying tech stocks, this one is pricey.

IonQ's shares have a price-to-sales ratio of 140, which is far beyond the technology sector's average P/S ratio of just under 9. That's a massive gap between the two, and it shows just how much more investors are paying to own IonQ right now.

Even if the company were profitable (it's not) and quantum computing were a sure thing (it isn't), this is a hefty price tag to pay for IonQ's shares and a clear warning for investors to stay away.

The company's losses are widening IonQ delivered impressive sales growth in the third quarter, with revenue rising 222% to nearly $40 million. ​​Despite that huge increase, the company's losses continued to expand.

IonQ's non-GAAP (adjusted) loss per share was $0.17, which was worse than its loss of $0.11 per share in the year-ago quarter. It's important to note that this decline is after the one-time accounting charge and acquisition costs from the quarter have been taken out.

IonQ's operating expenses are rising, too, and increased to $208 million in the third quarter, up from about $65 million in the year-ago quarter. Even with its impressive sales growth, the company continues to ramp up spending to a degree that its losses are expanding instead of narrowing.

Today's Change

(

-2.00

%) $

-1.01

Current Price

$

49.44

Quantum computing speculation is sky high This isn't IonQ's fault, per se, but the company's share price has benefited from the speculative nature of the quantum computing market. Many tech companies, even ones working on quantum computing, say that practical use cases for the technology are still years away.

Consider that Alphabet, which has made several important advancements in quantum computing, says that "useful" quantum computers are still five to 10 years away.

Investors have been very optimistic about speculative investments for some time, but we're already beginning to see the tide turning for certain stocks, including IonQ. The company's share price rose just 9% in 2025 -- compared to the S&P 500's gain of nearly 17%.

If the economy slows down, you can expect investments in speculative corners of the market, including quantum computing, to slow as well. Investors have enjoyed great times in the market, partially thanks to artificial intelligence stocks. But if they catch wind of a recession or begin to worry that more layoffs are on the horizon, they'll likely flee to safer investments.

Don't buy IonQ stock This quantum computing stock looks more like a gamble right now than a solid investment. IonQ's shares are too expensive, its losses are too wide, and the quantum computing market still has much to prove over the coming years. All of these reasons combined should point investors away from buying IonQ stock right now.

HomeETFs and Funds AnalysisETF Analysis

SummaryThe WisdomTree U.S. LargeCap Dividend Fund offers a diversified, value-oriented portfolio of 309 U.S. dividend stocks with risk-based screening.DLN underperforms the S&P 500 in total return but delivers lower volatility and a more balanced sector allocation, especially less tech concentration.Despite a lower yield and dividend growth rate, DLN has delivered a high total return and Sharpe ratio compared to key competitors since 2011.DLN suits investors prioritizing total return and sector diversification over yield, especially those wary of mega-cap and tech-heavy benchmarks.Quantitative Risk & Value members get exclusive access to our real-world portfolio. See all our investments here » champpixs/iStock via Getty Images

This article updates my review of January 2025 in light of current holdings and recent performance.

DLN strategy WisdomTree U.S. LargeCap Dividend Fund (DLN) was launched on 06/16/2006 and tracks the WisdomTree U.S. LargeCap Dividend

Analyst’s Disclosure:I/we have a beneficial long position in the shares of JNJ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Dog face - cute happy jack russell pet puppy looking in the grass, web banner with copy space

getty

The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index’s top payers dish up to 6.8%. Collectively, they provide 3X more yield than the miserly S&P!

We’ll review every one of the Dow’s 10 Dogs (and their dividends) in a moment. First, a refresher on how the “Dogs of the Dow” strategy works:

After the final close of 2025, we identify the 10 highest-yielding stocks in the Dow Jones Industrial Average.The strategy buys all 10 stocks in equal amounts and holds them for the full calendar year.At the end of the year, the stocks are sold. And the next 10 highest-payers are purchased.The strategy works because it is contrarian. High yields for blue chips are a signal of value. These stocks aren’t going out of business—they are merely out of favor.

Are America’s blue chips going out of business in 2026? I think not. So “the Dogs of the Dow” suggests we buy these stocks when their prices are lower, their yields are higher, and the chances of a bounce-back are elevated—it’s the contrarian way!

2025 Dogs of the Dow

Contrarian Outlook

Obviously, lopsided gains in Johnson & Johnson (JNJ), International Business Machines (IBM) and a couple other stocks helped the Dogs outdo the broader Dow. That’s the case every year—and an argument (for some investors) to cherry-pick the most interesting Dog components rather than blindly buying the group.

MORE FOR YOU

And who do we have to choose from in 2026?

2026 Dogs of the Dow

Contrarian Outlook

The Dogs’ average yield, which started 2026 north of 3%, is still shy of what we need to retire on dividends alone. So the upside potential of these blue chips is an important consideration, too.

Let’s keep that in mind as we evaluate each of 2026’s 10 Dow Dogs. We’re looking for the total package here: companies that can both deliver the cash and punch above their weight in the year to come.

Dogs Of The Dow #10: Johnson & JohnsonThe Skinny: In 2025, Johnson & Johnson (JNJ, 2.5% yield to start 2026) gave us a prime example of what we want out of our Dividend Dogs. Those who jumped on the pharma company’s shares locked in a yield that was well above JNJ’s historical averages, then the stock rocketed to the mean and a 47% total return.

Fundamental drivers? Strength in the company’s immunology, oncology, and medical-tech offerings; launches of new indications for Tremfya and Rybrevant plus Lazcluze; and the announcement that JNJ would spin off the DePuySynthes orthopedics business.

JNJ Yield Chart

Ycharts

What Has to Go Right in ‘26: JNJ is still a dog, but it’s starting with a modest 2.5% yield—good but not great for JNJ. It needs continued successes to offset competition to its autoimmune blockbuster Stelara. Legal defense of its talcum powder would help, too. In late 2025, a Baltimore jury ordered J&J to pay $1.5 billion in the largest-ever award to a talc plaintiff—a ruling the company said it would appeal.

Dogs Of The Dow #9: NikeThe Skinny: Nike (NKE, 2.6% yield) is the first of three new Dogs in 2026. It has been in freefall since late 2021, losing more than 60% of its value in that time—including a nearly 15% drop across 2025 that pushed its yield into the Dow’s top 10. Nike has been hobbled by numerous problems, including shifting consumer trends, supply chain issues, tariff complications and struggles at its brick-and-mortar locations. And while it closed out 2025 with a Street-beating earnings report, it did so while reporting slumping sales in China. The company also announced its 24th consecutive annual dividend increase, but it was a meager 2% bump that was much smaller than in recent years.

What Has to Go Right: In 2024, the company hired longtime Nike veteran Elliott Hill to replace John Donahoe as CEO, and the company is now roughly a year into its turnaround strategy. The company is trying to “lead with sport” again, realigning thousands of employees around core categories including running, basketball and sportwear. It’s also repairing relationships with wholesalers and pulling back on discounting. Profits are expected to take a big step back this year—current fiscal 2026 estimates would fall just shy of covering the payout—before rebounding significantly in fiscal 2027. And even then, the stock isn’t cheap, trading at 27 times next year’s estimates. If there’s any silver lining, it’s that NKE shares rarely yield this much.

Dogs Of The Dow #8: Home DepotThe Skinny: Home Depot (HD, 2.7% yield) is another new Dog for 2026 following an up-and-down 2025 that ultimately resulted in a nearly 10% loss for shareholders. Tariffs are partially to blame here, as are generally more cautious consumers. But we can also point the finger at a stagnant housing market (and an uncertain outlook) that’s keeping a lot of buyers on the sidelines.

What Has to Go Right: The American economy needs a sense of direction. “On the one hand, you look at certain economic indicators, and you say, geez, things are pretty good,” CEO Ted Decker said during the company’s third-quarter earnings call. “You look at GDP, you look at PCE, those are both strong. But on the other hand, what’s impacting us in home improvement is the ongoing pressure in housing and incremental consumer uncertainty.” The U.S. is begging for housing investment; the industry has been underbuilding for years, and nearly three-quarters of the nation’s existing homes are 25 years old or greater. But something must unleash that investment for Home Depot, whose bottom line and stock price have gone stale.

HD Total Returns

Ycharts

Dogs Of The Dow #7: UnitedHealth GroupThe Skinny: The third new Dog, UnitedHealth Group (UNH, 2.7% yield), was already staring at uncertainty heading into 2025 after its CEO, Brian Thompson, was shot and killed in December 2024. But Wall Street didn’t turn on the stock until April, when the company drastically cut back its annual earnings forecast because of high medical costs in its Medicare Advantage plans. It was hardly the only health insurer to suffer, but the pain was most acute at UNH as the nation’s largest provider of the private Medicare plans.

What Has to Go Right: A lot. The same pressures that weighed on UNH are expected to remain persistent in 2026—namely, the high medical utilization that’s tamping down profit margins. The company has also had to shuffle its C-suite, including bringing former CEO Stephen Hemsley back to run the ship. But the administration seems focused on driving down this insurer’s margins to cut costs (and keep inflation low, much like it’s trying to keep energy costs at bay). Like with many of these dogs, UnitedHealth’s yield is near historic highs. But it’s still a sub-3% payday trading at 20 times significantly reduced estimates.

Dogs Of The Dow #6: AmgenThe Skinny: Biotech Amgen (AMGN, 2.9% yield) did just about everything it could to get out of the doghouse in 2025, gaining 30% across the year. The stock really took off in November after a beat-and-raise Q3 report, helped in part by a 40% surge in sales of its cholesterol-lowering blockbuster treatment Repatha.

What Has to Go Right: Amgen is, among other things, a play on rare diseases. More than 10,000 exist today, but only 5% have approved medicines. Amgen is one of the most established biotechnology stocks, giving it a blend of R&D and manufacturing know-how to get these drugs to market—and the capital to identify and acquire other potential blockbusters. So for 2026, AMGN just needs to keep doing what it’s doing in growing its rare-disease drug sales. That said, one potential catalyst is an early-stage drug in a pretty crowded space: obesity. Any positive developments from its MariTide monthly injectable for obesity could further propel shares.

AMGN Revenue Growth

Ycharts

Dogs Of The Dow #5: Coca-ColaThe Skinny: Owners of Coca-Cola (KO, 2.9% yield) had little to complain about in 2025, bringing home a 15% total return from a defensive stock despite a great year for the overall market. Most of those gains came in one big chunk, however—the stock rocketed in February 2025 after a Street-beating Q4 report that showed rising global demand. After that, it didn’t do much of anything despite continuing to post upside surprises throughout the rest of the year. It’s on track to finish the 2025 financial year with low-single-digit top- and bottom-line growth.

What Has to Go Right: Coca-Cola is a master of staying ahead of consumer trends, whether that’s positioning its legacy products or adding to its already enormous stable of brands. I’ve mentioned for a couple of years that a popular worry among KO bears is the rise of GLP-1 drugs—and they could eventually take a more noticeable bite—but for now, even magic diet drugs can’t put a dent in Coke. Obviously, any pickup in global consumer spending could end up being a windfall for Coke. Pullbacks in growthier sectors could also push investors to double up on KO shares, too.

Dogs Of The Dow #4: Procter & GambleThe Skinny: Procter & Gamble (PG, 3.0% yield) entered 2025 as the “last Dog in,” and even a halfway decent 2025 could have kept it off the list this year. Instead, it laid an egg, delivering a slow, steady and substantial 12%-plus loss that, on a total return basis, represented the worst year for P&G shareholders since 2008. We might expect some underperformance from defensive consumer-staples names when the market keeps setting new highs, but deep red ink? The problem for Procter & Gamble is that 2025’s bull market came despite weakening consumer spending. And while that might seem like a recipe for many staples names, P&G is premium-priced in many categories—and when the going gets tough, the tough start stocking up on Walmart (WMT) and Costco (COST) white-label products instead.

What Has to Go Right: For one, the market could recognize that while things aren’t exactly rosy for Procter & Gamble, the arrow is still pointed in the right direction—the company’s full-year 2025 results, due out later this month, are still expected to show improvement on the top and bottom lines, and the pros expect the same for 2026. P&G is showing strength in emerging markets including China and Latin America. Meanwhile, the company is eyeing an eventual national launch of its Tide evo “laundry tiles” among other updates to its product lineup. Another healthy bump to the dividend wouldn’t hurt, either, and PG has the room to do it.

PG Dividend Magnet

Ycharts

Dogs Of The Dow #3: Merck & Co.The Skinny: Merck & Co. (MRK, 3.2% yield) started last year in the middle of a slide and kept on slipping, eventually losing 45% of its value between June 2024 and May 2025. That’s largely because Merck’s status as a monster drugmaker has been built on a mighty unsteady frame. Specifically, a single product—Keytruda—accounts for a little less than half the company’s revenues. It’s one heckuva drug, approved for some 40 indications covering about 20 different cancers. While it won’t start to lose exclusivity until late 2028, Wall Street has started to fret over the company’s ability to fill that sales hole. All that said, things looked a lot less bleak in the second half of 2025, with shares rebounding by about 40% off the bottom and finishing the year with a total return of about 10%.

What Has to Go Right: The same thing that started to go right in 2025: Wall Street believing that Merck has solved “the Keytruda problem.” Part of that includes finding new uses for Keytruda, including positive recent trial data on its use, in combination with Pfizer’s and Astellas’ Padcev, to treat muscle-invasive bladder cancer. It’s also launching a faster-acting version of the drug: Keytruda Qlex. But outside of that, MRK now has 16 cancer treatments in late-stage trials, and it has made deals to acquire companies such as Verona Pharma and Cidara Therapeutics to further shore up its pipeline.

Dogs Of The Dow #2: ChevronThe Skinny: Chevron (CVX, 4.5% yield) largely survived 2025’s “Liberation Day” drop in oil prices, posting a total return of about 10% across a rocky year for the entire energy sector. The announcement of massive tariffs on most of America’s trading partners sent the commodity plunging by about 15% last spring—even though oil itself wasn’t a target of the levies, fear of the global economy grinding to a halt dragged oil into the dirt. CVX shares spent the rest of the year playing catch-up. Worth noting: Chevron’s last earnings report of the year, in late October, showed booming production in the wake of its Hess acquisition, which closed in July.

What Has to Go Right: Chevron is a victim of its own generosity, doomed to remain a Dow Dog barring an unforeseen catalyst that could double CVX shares overnight. That’s unlikely, of course—even if oil and natural gas prices skyrocketed, the wide-ranging nature of this integrated oil giant wouldn’t benefit as directly as a lot of pure-play energy E&P firms would. Also, the sector has been thrown a serious curveball just a few days into 2026. America’s ouster in Venezuela initially sent the energy sector aloft amid President Donald Trump’s suggestions that he would open the country’s oilfields for business. Chevron is the only American firm that currently operates in the country, and even then under a license that only allows for limited production. But even assuming a much friendlier environment for U.S. firms, experts estimate it would take tens of billions of dollars of investment and many years to meaningfully ramp up production.

Dogs Of The Dow #1: VerizonThe Skinny: Verizon (VZ, 6.8%) continued to squeeze blood from a stone for yet another year. It’s on pace to deliver low-single-digit revenue and earnings growth for full-year 2025. Management took its meager profit growth and delivered a 2% bump in the payout. And shares appreciated by just about as much—of course, the total return looked a lot better thanks to the outsized distribution. That doesn’t sound like much to get excited about, but that’s a relatively good year for a company whose stock has lost 13% of its value (on a pure price basis) over the past decade.

What Has to Go Right: At least someone isn’t satisfied with the status quo. “When I look at our performance objectively, Verizon is clearly falling short of our potential,” former PayPal CEO Dan Schulman, who took the reins at Verizon in October 2025, said amid the company’s third-quarter earnings report. “Our primary objective is to build loyalty and drive significant improvements in retention … Verizon will no longer be the hunting ground for competitors looking to gain share. We are reinventing how we operate to make Verizon more agile and efficient.” It’ll take a lot more than fresh, angry blood in the C-suite, of course. Verizon has been trying to secure its subscribers with three-year price locks and better customer service. Meanwhile, VZ remains dirt-cheap at 8 times next year’s earnings, and its 7% yield is in a different area code compared to most blue chips.

Brett Owens is Chief Investment Strategist for Contrarian Outlook. For more great income ideas, get your free copy his latest special report: How to Live off Huge Monthly Dividends (up to 7.6%) — Practically Forever.

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint

• Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint

• The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301

HAYWARD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that the first patient treated in Cohort 1 of the BB-301 Phase 1b/2a clinical study (NCT06185673) evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy (OPMD) has completed the 24-month post-treatment assessment. At the 24-month follow-up timepoint, Patient 1 continued to demonstrate robust, disease-modifying outcomes. At the 24-month follow-up timepoint, Patient 1 demonstrated deepening improvements in post-swallow pharyngeal residue as compared to the final pre-treatment timepoint and the 12-month post-treatment follow-up timepoint as assessed by x-ray-based swallowing studies. Additionally, Patient 1 experienced deepening improvements in total dysphagic symptom burden as assessed by the Sydney Swallow Questionnaire (SSQ). The first 4 patients in Cohort 1 have now completed the 12-month statistical follow-up period for the Phase 1b/2a study, and all 4 Completers continued to demonstrate durable response to BB-301. All 4 Cohort 1 Completers met the pre-specified statistical criteria for response to BB-301 defined by Benitec which require improvement across 2 or more of the 5 categories of assessment comprising the Responder Analysis1.

“Progressive dysphagia is the most severe, life-threatening complication of OPMD, and we are extremely excited to observe safe, durable, disease-modifying outcomes for the patients treated with BB-301,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma Inc. “Durable improvements in the dysphagic symptom burden can have a profound impact on the lives of patients living with OPMD, and we remain singularly focused on advancing BB-301 through development to improve the lives of all OPMD patients. We look forward to engaging with the U.S. Food and Drug Administration (FDA) in mid-2026 to confirm the BB-301 pivotal study design and continuing to present interim clinical results at future medical conferences. We extend our deepest gratitude to the patients and families participating in the clinical study and to the investigators and clinical teams for their dedication to advancing new treatment options.”

Updated Interim Clinical Study Results

24-Month Post-Treatment Follow-Up for Patient 1 of Cohort 1

At the 24-month post-BB-301 treatment follow-up timepoint, Patient 1 of Cohort 1 continued to demonstrate robust, disease-modifying outcomes. At the 24-month follow-up timepoint, Patient 1 demonstrated deepening improvements in post-swallow pharyngeal residue as compared to the final pre-treatment timepoint and as compared to the 12-month post-treatment follow-up timepoint as assessed by videofluoroscopic swallowing studies (VFSS). Patient 1 also experienced deepening improvements in total dysphagic symptom burden as assessed by the Sydney Swallow Questionnaire (SSQ).

Pharyngeal Area at Maximum Constriction (“PhAMPC”), as assessed by VFSS, represents the functional capacity of the pharyngeal constrictor muscles during the swallowing cycle At the 24-month post-treatment timepoint, Patient 1 demonstrated durable functional improvement of pharyngeal constrictor-mediated throat closure, as the 12-month post-treatment improvements were perfectly maintained at the 24-month post-treatment timepointAs compared to the final pre-treatment visit, Patient 1 demonstrated a 27% improvement in PhAMPC (throat closure) at the 12-month post-treatment timepoint (27% improvement in throat closure at the peak of swallowing as compared to the final pre-treatment assessment), and the 27% improvement in PhAMPC was maintained at the 24-month post treatment timepoint (27% improvement in throat closure at the peak of swallowing as compared to the final pre-treatment assessment), indicating durable improvement in pharyngeal muscle function during swallowing
Normalized Residue Ratio Scale-Valleculae (NRRSv), as assessed by VFSS, represents the quantity of food and liquid material (residue) remaining in the vallecular region of the throat upon completion of a swallow (post-swallow residue) Elevated levels of post-swallow residue in the vallecular region of the throat have been shown to correlate with increased risk of aspiration eventsAt the 24-month post-treatment timepoint, the throat-emptying ability of Patient 1 continued to significantly improve for liquids and solid foodAs compared to the final pre-treatment visit, Patient 1 demonstrated a 35% improvement in NRRSv at the 12-month post-treatment timepoint (35% reduction in post-swallow residue in the vallecular region as compared to the final pre-treatment assessment), and at the 24-month post-treatment timepoint Patient 1 demonstrated a 60% improvement in NRRSv (60% reduction in post-swallow residue in the vallecular region as compared to the final pre-treatment assessment) exemplifying a deepening of the improvement in swallowing efficiency over time following the administration of BB-301
Total Pharyngeal Residue (TPR), as assessed by VFSS, represents the quantity of food and liquid material (residue) remaining in the throat upon completion of a swallow (post-swallow residue) At the 24-month post-treatment timepoint, the throat-emptying ability of Patient 1 continued to significantly improve for liquids and solid foodAs compared to the final pre-treatment visit, Patient 1 demonstrated a 32% improvement in TPR at the 12-month post-treatment timepoint (32% reduction in post-swallow residue as compared to the final pre-treatment assessment), and at the 24-month post-treatment timepoint Patient 1 demonstrated a 39% improvement in TPR (39% reduction in post-swallow residue as compared to the final pre-treatment assessment) exemplifying a deepening of the improvement in swallowing efficiency over time following the administration of BB-301
Sydney Swallow Questionnaire, a validated 17-item patient-reported outcome instrument, represents the total dysphagic symptom burden experienced by a patient At the 24-month post-treatment timepoint, the total dysphagic symptom burden continued to significantly declineAs compared to the final pre-treatment visit, Patient 1 experienced a 64% improvement in SSQ total score at the 12-month post-treatment timepoint (64% reduction in total dysphagic symptom burden as compared to the final pre-treatment assessment), and at the 24-month post-treatment timepoint Patient 1 experienced a 78% improvement in SSQ total score (78% reduction in total dysphagic symptom burden as compared to the final pre-treatment assessment) exemplifying a deepening of the improvement in total dysphagic symptom burden over time following the administration of BB-301
Analysis of Study Completers (12-Month Post-Treatment Follow-Up)

A Responder Analysis was developed to facilitate standardized evaluation of BB-301 efficacy for each patient. The Responder Analysis consists of multiple discrete response categories that collectively assess the dysphagic symptom burden in patients with OPMD.

These response categories include:Patient-Reported Outcome: Patient-reported oropharyngeal dysphagia as assessed by the Sydney Swallow Questionnaire (SSQ) total scoreVideofluoroscopic Swallowing Study (VFSS) Assessments: Pharyngeal constrictor muscle function as estimated by the Pharyngeal Area at Maximum Constriction (PhAMPC)Swallowing efficiency as measured by NRRSv and Total Pharyngeal Residue %(C2-4)2Frequency of pathologic sequential swallows (SEQ) Functional Swallowing Capacity: Cold-Water Timed Drinking Test (CWDT)Following completion of the 12-month post-treatment follow-up timepoint, each discrete response category is evaluated for each study Completer using prespecified statistical criteria
Results of the statistical characterization of each response category are combined into a single scoring framework that facilitates the overall assessment of clinical benefit achieved by each patient following treatment with BB-301A total Score of 5 is possibleResponder status for each patient will be assigned based on the achievement of statistical criteria for at least 2 out of 5 discrete response categories (≥40%) Responder Analysis for Study Completers: Patients 1-to-4 of Cohort 1

All 4 Cohort 1 Completers were formal Responders to BB-301, demonstrating durable response to BB-301 at the conclusion of the 12-month statistical follow-up period.

About BB-301
BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA.

About Benitec Biopharma, Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Irina Koffler
LifeSci Advisors, LLC
(917) 734-7387
[email protected]

1 (Final+Webcast+Slides)BENITEC,+2025NOV01.pdf

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f653cced-806c-4f5a-a3ea-991da27438a7

Steam turbines will start powering AI workloads in 2028.

Red-hot data center designer, builder, and operator Applied Digital (APLD +17.97%) reported incredible growth in the second quarter of fiscal 2026. Revenue soared 250% year over year to $126.6 million as demand for AI data centers exploded.

Applied Digital delivered the first 100 MW of AI computing capacity at its Polaris Forge 1 campus, which will eventually provide 400 MW of total capacity for CoreWeave. The company also signed a 15-year lease with an unnamed U.S. hyperscaler for 200 MW of AI capacity at the Polaris Forge 2 campus, a deal expected to generate approximately $5 billion in revenue.

Image source: Getty Images.

A major bottleneck for the AI industry While demand for AI data centers isn't slowing down, the AI industry is facing a difficult problem. The bottleneck isn't GPUs or buildings, but power generation. AI data centers require enormous amounts of power, and the electric grid simply can't keep up.

Tech giants hungry for more AI computing capacity have been getting creative in their attempts to address this problem. Multiple tech giants are exploring nuclear power, with Meta Platforms signing a 20-year deal with Constellation Energy last year to revive a nuclear power plant in Illinois. Unfortunately, bringing meaningful nuclear power generation capacity online will likely take years.

Another solution is using gas turbines installed directly within AI data centers. This bypasses the problem of waiting for enough power generation capacity to come online from electric utilities. Some companies have even installed retired commercial aircraft engines to keep AI servers running.

While gas turbines are a great solution, a severe shortage threatens to limit how quickly Applied Digital and other data center builders can expand their footprints. John Ketchum, CEO of NextEra Energy, noted last June that a new gas-fired power generation facility would not come online until 2032 due to a shortage of gas turbines . Major gas turbine manufacturers estimated early last year that customers could be waiting 7 to 8 years for new gas turbines.

Applied Digital CEO Wes Cummins described the problem during the second quarter earnings call: "If you get in lines for a traditional natural gas turbine right now, if we put an order in today, we're probably not getting delivery until 2031, 2032 for that equipment. We need power earlier than that."

Applied Digital aims to increase its capacity to 5 gigawatts over the next five years, and the company is currently in advanced discussions for 900 MW of capacity. For any of that to happen, the company needs to solve its power generation problem. In the same earnings call, Cummins described a potential solution.

Today's Change

(

17.97

%) $

5.74

Current Price

$

37.68

Looking to the past to solve AI's toughest problem Applied Digital signed a limited notice to proceed with Babcock & Wilcox in November to deliver 1 GW of power. B&W has been in operation since 1867, specializing in the design and manufacture of steam turbines. Steam turbines have been around for more than a century, and now they're set to be used to power the AI revolution.

B&W will design and install multiple 300 MW natural gas-fired power plants, each featuring boilers and steam turbines, in one of Applied Digital's AI data center campuses. The plan is for the new power generation capacity to come online in 2028, years before standard gas turbines could be installed. The steam turbine generator sets will be supplied by Siemens Energy.

"It's using steam turbines, think of coal plant boilers, but we're using natural gas. That company has actually made a lot of coal-to-natural gas conversions over the past decade plus. And what it allows us to do is go to market earlier," said Cummins during the earnings call.

If Applied Digital has the capability to bring AI data centers online 3 or 4 years earlier than the competition, the company can sign big multi-year deals today to lock in hyperscalers desperate to boost capacity. This competitive advantage won't last forever, but it appears that Applied Digital is the first data center company to turn to steam turbines for power generation. The deal with Applied Digital marked B&W's entry into the AI data center market.

Demand for AI computing capacity isn't slowing down. Applied Digital's 5 GW target is certainly realistic given the demand environment, but securing sufficient power generation capacity was likely to be a challenge. By turning to century-old technology, the company won't have to wait until the 2030s to bring new AI data centers online and continue growing its revenue at an impressive rate.

Nvidia is set for monster growth again in 2026.

Nvidia (NVDA 0.05%) is a company like no other. It has dramatically risen to become the world's largest company by market cap and is growing at a rate that no other trillion-dollar company has ever achieved.

Furthermore, it won't be done growing anytime soon. Nvidia's stock isn't in a bubble; it's a real company generating real profits, growing at an unbelievable pace.

I think the company is set to make history in 2026 on two fronts, and I think both are fantastic reasons to buy the stock now.

Image source: Getty Images.

1. Nvidia will become the most profitable company in the world in 2026 Currently, Alphabet (GOOG +1.05%) (GOOGL +0.96%) is the world's most profitable company. Over the past 12 months, Alphabet generated nearly $125 billion in profits, while Nvidia was just shy of $100 billion.

NVDA Net Income (TTM) data by YCharts. TTM = trailing 12 months.

While Alphabet is growing at a solid pace, it's nothing compared to Nvidia. For 2026, Wall Street analysts expect Alphabet's revenue to rise at a 14% rate. For fiscal year 2027 (ending January 2027), these analysts expect Nvidia's revenue growth to be a jaw-dropping 50%. Assuming that no events tank either company's profit margins, and they can maintain the same level they have over the past 12 months (Alphabet's was 32%, and Nvidia's was 53%), Nvidia will pass Alphabet as the world's most profitable company.

For next year, Alphabet would generate about $146 billion in profits, while Nvidia racks up $170 billion. That's a huge milestone for Nvidia to achieve, and if future data center buildout projections are to be believed, Nvidia's profits could rocket higher in the years beyond 2026. Nvidia believes that global data center capital expenditures will reach $3 trillion to $4 trillion by 2030. With its graphics processing units (GPUs) comprising up to half of those costs, there is a huge potential market for Nvidia to grow into over the next few years.

This new profitability level will also cause Nvidia to make history in another way.

2. Nvidia will become the first $6 trillion company Nvidia was the first $5 trillion company but has since pulled back from that level and sits at about a $4.6 trillion market cap. However, if Nvidia's projected growth pans out, it won't stay there long. Should Nvidia's market cap stay put and it deliver the $170 billion in profits investors expect, that would value Nvidia's stock at 27 times earnings. While 27 times earnings isn't necessarily cheap by itself, it fails to factor in the massive growth investors expect for the artificial intelligence market.

Today's Change

(

-0.05

%) $

-0.09

Current Price

$

184.95

As a result, looking at Nvidia's forward earnings ratio is much smarter. Nvidia tends to trade around 40 times forward earnings. So, if Nvidia achieves $170 billion in revenue and is valued at 40 times forward earnings, that means the company would be worth $6.8 trillion. That's easily in the $6 trillion range and nearly to the $7 trillion level.

No other company is in contention with Nvidia to achieve these levels, so it's safe to say that it will be the first to breach these notable levels if its projections pan out. If Nvidia rises to a $6.8 trillion market cap throughout 2026, you're going to want to buy the stock now.

That would indicate the stock would rise nearly 50% for the year. Few stocks can deliver that growth level, let alone the world's largest company. I think Nvidia is assured to make history in 2026 and deliver some promising results along the way. It's one of the largest holdings in my portfolio, and I think investors would be wise to make it their largest as well.

This clinical-stage biotech developing metabolic therapies reported a notable insider sale amid a challenging year for its stock.

Greg Zante, the chief financial officer of Viking Therapeutics (VKTX +1.07%), reported the direct sale of 57,661 shares of the biotech in multiple open-market transactions valued at $1.9 million, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)57,661Transaction value$1.9 millionPost-transaction shares (direct)189,891Post-transaction value (direct ownership)$6.1 millionTransaction value based on SEC Form 4 weighted average purchase price ($32.90); post-transaction value based on position value at the Monday transaction price.

Key questionsHow significant was this sale relative to Greg Zante's recent trading activity?
This 57,661-share disposition is above his recent median sale size of 50,309 shares since May, but the high proportion (23.29%) of direct holdings impacted is explained by his diminished available share balance after prior transactions.Did Zante retain substantial equity exposure after the transaction?
Post-sale, Zante directly holds 189,891 shares (valued at $6.1 million as of Monday) and 91,000 options outstanding.How does the company's recent stock performance contextualize this transaction?
Viking Therapeutics shares closed at $32.14 on Monday, reflecting a one-year decline of 18.62%.Company overviewMetricValuePrice (as of Monday)$32.90Market capitalization$3.62 billionNet income (TTM)($237.39 million)1-year price change(18.62%)Company snapshotViking Therapeutics develops clinical-stage therapeutics targeting metabolic and endocrine disorders, with a pipeline including VK2809 (NASH/NAFLD), VK5211 (hip fracture recovery), VK0612 (type 2 diabetes), and VK0214 (X-linked adrenoleukodystrophy).The company operates a research-driven business model focused on the development and potential future commercialization or licensing of proprietary drug candidates.Primary customers will include healthcare providers, hospitals, and specialty clinics treating metabolic, endocrine, and rare disease patients, pending regulatory approvals.Viking Therapeutics is a clinical-stage biotechnology company focused on advancing novel therapies for metabolic and endocrine diseases. With a lean team and a diversified pipeline, the company aims to address significant unmet medical needs through innovative small molecule therapeutics. Its strategic emphasis on selective receptor modulators positions it to compete in high-value specialty pharmaceutical markets as its assets progress through clinical development.

What this transaction means for investorsViking Therapeutics’ shares have fallen roughly 19% over the past year, sharply underperforming the S&P 500’s approximately 18% gain, even as the company continues to advance a deep metabolic pipeline. Earlier this month, the company completed enrollment in a Phase 1 maintenance dosing study for VK2735, its dual GLP-1 and GIP agonist for obesity, while continuing two large Phase 3 trials with data expected later this year. Progress across those programs remains the dominant driver of long-term value rather than short-term share price volatility.

Against that backdrop, CFO Greg Zante sold 57,661 shares at a weighted average price of $32.90, totaling about $1.9 million, according to an SEC filing. Crucially, the Form 4 notes the shares were automatically sold to satisfy tax withholding obligations tied to the vesting of restricted and performance-based stock units. In other words, the transaction was non-discretionary and did not reflect a judgment call on valuation or clinical outlook.

After the sale, Zante still holds 189,891 shares directly and 91,000 options, maintaining substantial exposure to future upside. The biggest takeaway? Tax-driven insider sales at development-stage biotechs say little about conviction, even if shares aren’t doing so well. Viking’s trajectory will hinge on clinical data quality and regulatory progress, not administrative equity events.

GlossaryInsider ownership: The percentage of a company's shares held by its executives, directors, or key employees.
Open-market transaction: The purchase or sale of securities on a public exchange, rather than through private arrangements.
Form 4: A required SEC filing disclosing insider trades by company officers, directors, or major shareholders.
Derivative context: Involvement of financial instruments like options or warrants whose value is based on underlying securities.
Options outstanding: The total number of unexercised stock options currently held by employees or insiders.
Direct ownership: Shares held personally by an individual, not through trusts or other entities.
Vesting: The process by which an employee earns the right to receive stock or options over time.
Clinical-stage: Refers to pharmaceutical products currently being tested in human clinical trials, not yet approved for sale.
NASH/NAFLD: Liver diseases: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
TTM: The 12-month period ending with the most recent quarterly report.
Selective receptor modulators: Drugs designed to target specific cell receptors to achieve desired therapeutic effects with fewer side effects.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.